Surufatinib Administration

DRUG2 trials

Sponsors

Sun Yat-sen University, Yefeng

Conditions

ChemoradiotherapyEsophageal Squamous Cell CarcinomaNeoadjuvant ImmunochemotherapyNeuroendocrine (NE) TumorsSurufatinibToripalimab

Phase 2

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT07086469

Sun Yat-sen UniversityChemoradiotherapy, Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy +2

Start: 2025-07-20End: 2029-07-19Target: 69Updated: 2025-11-17

Unknown Phase

Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors

Not yet recruitingNCT07780539

YefengNeuroendocrine (NE) Tumors

Start: 2026-09-01End: 2031-08-31Target: 60Updated: 2026-08-21